Shigella flexneri serotype 1b (S. flexneri 1b)

Shigella flexneri serotype 1b is a specific subgroup of the Gram-negative, facultative intracellular bacterium Shigella flexneri, which is a leading cause of bacillary dysentery (shigellosis) worldwide, particularly in developing nations. This serotype is defined by the unique chemical structure of its O-antigen—the distal polysaccharide component of its lipopolysaccharide (LPS)—which contains a tetrasaccharide backbone modified by specific acetylation and glucosylation patterns. The bacterium utilizes a type III secretion system (T3SS) to invade human colonic epithelial cells, where it replicates and spreads from cell to cell, triggering intense mucosal inflammation, tissue destruction, and bloody diarrhea. In the context of therapy, Shigella flexneri serotype 1b is the primary target of several classes of antibiotics, including fluoroquinolones like ciprofloxacin and macrolides like azithromycin. However, the rapid emergence of multidrug-resistant (MDR) isolates has made serotype 1b a significant challenge for clinical management. Modern drug discovery efforts are focused on identifying novel virulence inhibitors that block bacterial entry into host cells and developing serotype-specific conjugate vaccines. These vaccines utilize the 1b O-antigen as a molecular target to elicit protective antibodies, aiming to provide long-term immunity against this highly infectious pathogen.

Other names

Shigella flexneri 1bS. flexneri 1bShigella flexneri serogroup B serotype 1b

Antibiotics target essential bacterial processes such as DNA replication via DNA gyrase inhibition (fluoroquinolones), protein translation via the 50S ribosome (macrolides), and cell wall synthesis (beta-lactams); investigational vaccines and monoclonal antibodies target the specific O-antigen structure to prevent bacterial invasion and promote immune clearance.